Following news from Pfizer on Friday, several pharmaceutical companies were among the significant losers on Friday. BioNTech was one of them.
Biontech SE is a German biotechnology company based in Mainz that has been listed on the stock exchange since the end of 2019. It is focused on the development and manufacture of active immunotherapies for a patient-specific approach to the treatment of cancer and other serious diseases.
The reason for the slump: Pfizer has developed a Corona drug and published top study results. The drug Paxlovid reduces hospitalizations or deaths due to Covid-19 by 89 percent, according to the company. While Pfizer shares rose sharply, Moderna and BioNTech share prices fell. At the end of the day, BioNTech was trading at -20.92%.
While investors are clearly running profits at Pfizer, the question is how best to act now at BioNTech and Moderna. For it is certain that vaccines will continue to be the tool of choice to combat the Corona pandemic. In addition, the fantasy is now in a completely different area – among other things, the possibilities seemingly significant with the help of mRNA technology in the field of cancer.
For more updates, follow us on Twitter:@JRC_Capital
